Literature DB >> 11493314

Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule.

T Hamada1, Y Nagata, M Tomita, W Salmhofer, T Hashimoto.   

Abstract

By immunoblot analyses of normal human epidermal extracts, the 230 kDa bullous pemphigoid antigen (BP230) is recognized by most bullous pemphigoid sera. By polymerase chain reaction using keratinocyte cDNA library as a template, we successfully amplified 3 cDNAs of about 3 kb, which covered whole human BP230 molecule. By inserting the cDNAs into bacterial expression vector pGEX, we prepared 3 different recombinant glutathione-S-transferase-fusion proteins, which roughly presented N-terminal domain, central rod domain and C-terminal domain of BP230. By immunoblotting using these 3 recombinant proteins, we demonstrated that the majority of bullous pemphigoid sera reacted clearly with multiple recombinant proteins of BP230, most frequently with C-terminal domain. We also examined sera of pemphigus vulgaris, pemphigus foliaceus and herpetiform pemphigus that showed BP230-like protein band by immunoblotting of epidermal extracts, as well as paraneoplastic pemphigus, for reactivity with the 3 recombinant proteins. In the study, we found that only very few of these non-bullous pemphigoid sera reacted with some of the recombinant proteins. These results indicate that the BP230 is specifically reacted by bullous pemphigoid sera, and that the immunoblotting using the BP230 recombinant proteins should be a useful tool for the diagnosis of bullous pemphigoid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493314     DOI: 10.1034/j.1600-0625.2001.100405.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  6 in total

1.  Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.

Authors:  S Emtenani; H Yuan; C Lin; M Pan; J E Hundt; E Schmidt; L Komorowski; J R Stanley; C M Hammers
Journal:  Br J Dermatol       Date:  2019-01-01       Impact factor: 9.302

2.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

3.  Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid.

Authors:  Eui Hyung Lee; Yeon Hee Kim; Sinyoung Kim; Song-Ee Kim; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2012-02-02       Impact factor: 1.444

Review 4.  Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid.

Authors:  Connor Cole; Luca Borradori; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2022-06-28

Review 5.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 6.  Diagnosis of Autoimmune Blistering Diseases.

Authors:  Mareike Witte; Detlef Zillikens; Enno Schmidt
Journal:  Front Med (Lausanne)       Date:  2018-11-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.